Therapeutic levels of aminocaproic acid in asian elephants (Elephas maximus)

Drugs that inhibit fibrinolysis, such as epsilon aminocaproic acid (EACA), are of increasing interest in human and companion animal medicine to prevent bleeding due to surgery, trauma, and other causes. EACA and related drugs have been associated with decreased mortality and decreased transfusion requirements in patients suffering from hemorrhage. These drugs may be especially valuable in elephants, as banked blood products are not available and therapeutic transfusions can be logistically challenging.

Scientists at Cornell University, College of Veterinary Medicine will use an in vitro model of hyperfibrinolysis to estimate the plasma level of EACA that effectively inhibits fibrinolysis in Asian elephant plasma. The results of this study will provide necessary groundwork for safely applying EACA in clinical situations in elephants decreasing morbidity and mortality due to hemorrhagic disorders, which include EEHV and reproductive tract disease.